Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)
Status
Conditions
Details and patient eligibility
About
The study aims to collect information on the current treatment patterns for Hepatitis C in participating countries. There is also a focus on patients receiving a daclatasvir-containing treatment regimen who will be followed prospectively for 12 months after treatment initiation to collect real-world data on effectiveness and safety of the treatment. Additional analysis will differentiate between selected subpopulations.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Adult (≥18 years at inclusion)
- Diagnosed with a chronic hepatitis C infection
- Whose physician has already decided to initiate a new HCV treatment or a new daclatasvir-containing regimen
- Informed consent to participate in the study
Exclusion Criteria:
- Participation in a clinical trial or an early access program for HCV therapies
Trial design
920 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal